Migdal Insurance & Financial Holdings’s Dr. Reddy's Laboratories RDY Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$485K	Hold	35,000	–	–	﹤0.01%	179
2025 Q4	$492K	Hold	35,000	–	–	﹤0.01%	179
2025 Q3	$489K	Sell	35,000 -20,000	-36%	-$288K	0.01%	179
2025 Q2	$827K	Sell	55,000 -20,000	-27%	-$286K	0.01%	149
2025 Q1	$989K	Sell	75,000 -25,000	-25%	-$345K	0.01%	145
2024 Q4	$1.57M	Sell	100,000 -57,500	-37%	-$864K	0.02%	131
2024 Q3	$2.5M	Hold	157,500	–	–	0.04%	103
2024 Q2	$2.38M	Buy	157,500 +30,000	+24%	+$430K	0.04%	118
2024 Q1	$1.87M	Buy	127,500 +67,500	+113%	+$986K	0.03%	118
2023 Q4	$837K	Buy	60,000 +40,000	+200%	+$535K	0.02%	176
2023 Q3	$264K	Buy	20,000 +10,000	+100%	+$135K	0.01%	216
2023 Q2	$125K	Hold	10,000	–	–	﹤0.01%	247
2023 Q1	$113K	Hold	10,000	–	–	﹤0.01%	307
2022 Q4	$104K	Hold	10,000	–	–	﹤0.01%	259
2022 Q3	$104K	Hold	10,000	–	–	﹤0.01%	259
2022 Q2	$111K	Hold	10,000	–	–	﹤0.01%	295
2022 Q1	$113K	Hold	10,000	–	–	﹤0.01%	336
2021 Q4	$131K	Hold	10,000	–	–	﹤0.01%	332
2021 Q3	$130K	Hold	10,000	–	–	﹤0.01%	331
2021 Q2	$147K	Hold	10,000	–	–	﹤0.01%	352
2021 Q1	$123K	Hold	10,000	–	–	﹤0.01%	432
2020 Q4	$143K	Hold	10,000	–	–	﹤0.01%	353
2020 Q3	$139K	Hold	10,000	–	–	﹤0.01%	450
2020 Q2	$106K	Sell	10,000 -11,000	-52%	-$112K	﹤0.01%	413
2020 Q1	$169K	Hold	21,000	–	–	﹤0.01%	321
2019 Q4	$170K	Sell	21,000 -6,000	-22%	-$47.4K	﹤0.01%	439
2019 Q3	$205K	Hold	27,000	–	–	﹤0.01%	468
2019 Q2	$201K	Hold	27,000	–	–	0.01%	469
2019 Q1	$219K	Hold	27,000	–	–	0.01%	399
2018 Q4	$204K	Sell	27,000 -5,000	-16%	-$35.2K	﹤0.01%	375
2018 Q3	$221K	Hold	32,000	–	–	﹤0.01%	506
2018 Q2	$204K	Sell	32,000 -32,500	-50%	-$205K	﹤0.01%	432
2018 Q1	$422K	Hold	64,500	–	–	0.01%	278
2017 Q4	$485K	Hold	64,500	–	–	0.01%	224
2017 Q3	$460K	Sell	64,500 -6,300	-9%	-$45.3K	0.01%	223
2017 Q2	$582K	Buy	70,800 +300	+0.4%	+$2.44K	0.01%	191
2017 Q1	$573K	Sell	70,500 -1,000	-1%	-$8.64K	0.01%	191
2016 Q4	$640K	Buy	+71,500	New	+$665K	0.02%	170

Other funds holding RDY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIM

Aikya Investment Management London, United Kingdom $345M AUM 10.59% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Migdal Insurance & Financial Holdings's RDY Position: Q1 2026 in Review

Migdal Insurance & Financial Holdings held its Dr. Reddy's Laboratories (RDY) position steady in Q1 2026 at 35,000 shares worth $485K. The position accounts for ﹤0.01% of the portfolio, ranked #179.

Migdal Insurance & Financial Holdings first reported a position in RDY in Q4 2016 and has held it in 38 quarters since. The position peaked at $2.5M in Q3 2024. 248 funds tracked by Wall St. Rank hold RDY as of Q1 2026.

Migdal Insurance & Financial Holdings held 35,000 shares of Dr. Reddy's Laboratories worth $485K as of Q1 2026.
Migdal Insurance & Financial Holdings left its Dr. Reddy's Laboratories share count unchanged in Q1 2026.
Dr. Reddy's Laboratories made up ﹤0.01% of Migdal Insurance & Financial Holdings's portfolio in Q1 2026, its #179 holding.
Migdal Insurance & Financial Holdings first reported a position in Dr. Reddy's Laboratories in Q4 2016 and has held it in 38 quarters since.
Migdal Insurance & Financial Holdings's Dr. Reddy's Laboratories position peaked at $2.5M in Q3 2024.
248 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q1 2026.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q1 2026, filed 14 May 2026.